SciFi Futures
← Concepts
Biotech & Medicine

Industrial ectogenesis (hatcheries)

Human beings produced entirely in machinery - eggs fertilized in vitro, embryos bottled on a moving conveyor, and infants decanted after a full engineered gestation, in predetermined numbers and grades.

In shortIndustrial ectogenesis (hatcheries), from Brave New World (Aldous Huxley, 1932), is at technology readiness level 2 of 9 (technology concept formulated) at its weakest link. Held back by Full-term ectogenesis. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $17B–68B.

The Central London Hatchery and Conditioning Centre fertilizes ova in vitro, uses the Bokanovsky Process to split one embryo into up to 96 identical twins, and carries bottled embryos along a 267-day conveyor before decanting.
Brave New World by Aldous Huxley, 1932Set in 2540On track514 years left to climb 6 TRL steps (85.7 yrs/step)

Closest todayIVF plus neonatal intensive care covers the two ends; artificial-placenta systems have supported preterm lambs for four weeks but no human trial has begun, and human embryo culture stops at about 14 days.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • criticalFull-term ectogenesisbottleneck
    Gestation from fertilization to term with no uterus at any stage is the whole premise and no part of the middle trimester has ever been done
    • The gap between day-14 embryo culture and artificial-placenta viability covers organogenesis, the hardest and least substitutable phase
    • No artificial implantation or placental organ exists to supply hormones and nutrient exchange during that gap
    • Scaling implies thousands of parallel units with sterility and uninterrupted power for nine months each
    TRL 2
    • The early half cannot be built without reconstructing implantation and placental exchange
      ✕3 blockers›
      • The placenta's endocrine and nutrient-exchange functions have not been reproduced by any device or culture
      • Maternal immune tolerance at the interface is not understood well enough to substitute for
      • Human implantation cannot be studied past the 14-day limit, so the critical window is inaccessible
      TRL 3
    • An engineered placenta is a vascularized tissue that must be grown, not just machined
      ✕4 blockers›
      • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
      • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
      • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
      • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
      TRL 4
      • Without a capillary network, tissue thicker than a few hundred microns dies
        ✕3 blockers›
        • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
        • Engineered endothelium is thrombogenic, so perfused constructs clot
        • No method guides anastomosis of a construct's vasculature to host vessels at scale
        TRL 3
      • Banked-cell organs are not patient-matched, so acceptance must be engineered
        ✕3 blockers›
        • Chronic antibody-mediated rejection proceeds even under current immunosuppression
        • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
        • No assay predicts which recipients can be safely weaned off drugs
        TRL 5
      • One organ needs 10^10-10^11 clinical-grade cells of several types
        ✕3 blockers›
        • Genomic instability and drift accumulate over the expansion needed for 10^11 cells
        • Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
        • Cost per cell at current media and reagent prices makes a printed organ unaffordable
        TRL 6
    • Supplies the late-gestation half of the problem
      ✕4 blockers›
      • Miniaturization - the lamb model weighs 1-3 kg while a 23-week human fetus is about 500 g, with shorter umbilical cannulation distances
      • Umbilical vessel vasospasm and thrombosis during cannulation and over weeks of support
      • Infection control in a continuously exchanged sterile fluid environment
      • No agreed proof-of-concept endpoint or animal model that maps onto human neonatal outcomes
      TRL 5
      • Sterile fluid exchange, nutrition and waste handling must run continuously without interruption
        ✕2 blockers›
        • Food production closure
        • Microbial and ecological stability over years
        TRL 5
      • Gas exchange through the umbilical circuit for weeks is the core function
        ✕3 blockers›
        • Blood-surface contact activates coagulation, so runs depend on anticoagulation that causes bleeding in fragile patients
        • Oxygenator plasma leakage and fiber fouling limit single-circuit life
        • Hemolysis and platelet consumption scale with pump shear and circuit length
        TRL 7
  • Supplies gas exchange, nutrition and the fetal fluid environment for the late-gestation stretch
    TRL 5
  • The conveyor replaces implantation and the placenta, which must first be understood well enough to substitute for
    TRL 3
  • Industrial output needs gamete supply decoupled from donors
    ✕3 blockers›
    • Human oocyte maturation needs months of follicle growth that culture cannot yet sustain
    • Meiotic recombination and chromosome segregation are error-prone outside the ovary, giving aneuploidy
    • Imprinting marks are set during germ-cell development and are mis-set in vitro, with no safety assay short of a live birth
    TRL 3
  • Producing scores of genetically identical individuals on demand is cloning, not twinning
    ✕3 blockers›
    • Incomplete epigenetic reprogramming of the donor nucleus produces placental defects and large-offspring syndrome
    • Efficiency is a few percent of transferred embryos, so each live birth consumes many donor eggs and surrogates
    • Donor egg supply is the limiting input for any primate-scale program
    TRL 5
  • Thousands of parallel gestation units imply sterile media, tissue and reagent production at industrial volume
    TRL 6

Who could unlock it

  • Across several requirements:
  • Jacob Hanna 2
  • Vitara Biomedical 2
  • Nicolas Rivron 2
  • Perinatal Life Support (PLS) consortium 2
Full-term ectogenesisTRL 2bottleneck
  • Jacob HannaResearcher, Weizmann Institute of Science
    Grew natural mouse embryos ex utero from E5.5 to E11 through organogenesis (Nature, 2021) and generated transgene-free post-gastrulation whole embryo models from naive stem cells (Cell Stem Cell, 2025); holds an ERC grant titled ExUteroEmbryogenesis
  • Alejandro Aguilera-CastrejonResearcher, Janelia Research Campus, HHMI
    Built the roller and perfusion ex utero culture platform in the Hanna lab and now works explicitly toward birthing a mouse from an incubator
  • Renewal BioStartup
    Israeli company co-founded by Hanna in 2022 that licensed the Weizmann ex utero and synthetic-embryo patents (about $9M raised via NFX) to grow early tissue as a cell source
  • Vitara BiomedicalStartup
    Working the opposite end of the same problem - fluid-filled support from roughly 22 weeks of human gestation onward, the only part of full-term ectogenesis anywhere near clinical use
Reconstructed implantation and placentationTRL 3
  • Jacob HannaResearcher, Weizmann Institute of Science
    Built the ex utero mouse embryo culture platform (Nature, 2021) that the 2026 extension into the fetal period is based on
  • Nicolas RivronResearcher, Institute of Molecular Biotechnology, Austrian Academy of Sciences
    Makes human blastoids that attach to hormonally primed endometrial organoids, and used the assay to screen compounds that block implantation
  • Ashley MoffettResearcher, University of Cambridge
    Showed uterine natural killer cells control extravillous trophoblast differentiation in early pregnancy (Cell Stem Cell, 2024), the core of maternal immune tolerance
  • Centre for Trophoblast ResearchAcademic lab
    Cambridge centre supplying the trophoblast organoid and placental-interface biology the rest of the field builds on
In vitro gametogenesisTRL 3
  • Conception BiosciencesStartup
    Reported the first stem-cell-derived human primary oocytes inside entirely iPSC-derived follicle structures, from a blood draw (June 2026)
  • Katsuhiko HayashiResearcher, Osaka University
    Produced healthy fertile mouse pups from iPSC-derived eggs (2016), the only complete mammalian IVG demonstration, and collaborates with Conception
  • Mitinori SaitouResearcher, ASHBi, Kyoto University
    Generated human oogonia from iPSCs (Science, 2018) and reconstituted human germline epigenetic reprogramming in vitro (Nature, 2024), defining the steps the field has to reproduce
  • GametoStartup
    Its iPSC-derived ovarian support cell product Fertilo produced the first live birth from stem-cell-assisted egg maturation (December 2024) and is in Phase 3 after a $44M Series C in August 2025
Artificial placenta for extreme prematurityTRL 5
  • Vitara BiomedicalStartup
    Philadelphia company founded in 2019 to commercialise the CHOP EXTEND fluid-filled neonatal support system; filed a $50M Series B offering in October 2024 and remains pre-clearance
  • Alan FlakeResearcher, Children's Hospital of Philadelphia
    Co-inventor of EXTEND; his group kept 105-118-day-gestation lambs alive on pumpless umbilical access with protected organ development (2017 onward)
  • Marcus DaveyResearcher, Vitara Biomedical
    Co-inventor of the EXTEND circuit and leads its preclinical research program
  • George MychaliskaResearcher, University of Michigan C.S. Mott Children's Hospital
    Runs the NIH-funded artificial placenta program in Robert Bartlett's ECMO lab, supporting premature lambs for up to several weeks with lung and brain protection
Somatic cell nuclear transfer cloningTRL 5
  • Qiang SunResearcher, Institute of Neuroscience, Chinese Academy of Sciences
    Cloned the macaques Zhong Zhong and Hua Hua (2018) and ReTro, the first cloned rhesus to reach adulthood, using trophoblast replacement (2024)
  • Institute of Neuroscience, Chinese Academy of SciencesGovernment lab
    The only group to have produced primate clones; its 2024 result consumed 113 transferred embryos for one surviving animal
  • ViaGen Pets and EquineCompany
    The commercial SCNT operation, cloning cats, dogs and horses and the Przewalski's horse Kurt; acquired by Colossal Biosciences in November 2025
  • Colossal BiosciencesStartup
    Uses cloning from edited cell lines as its route to live animals and bought ViaGen in 2025 to bring that throughput in-house

Beyond engineering

  • The 14-day limit on human embryo culture, codified in law in several jurisdictions, blocks the research the middle of the problem requires
  • Legal status of a gestating fetus outside a body, and of the facility that owns it
  • Deliberate caste stratification by prenatal treatment is the novel's point and would be illegal discrimination
  • Consent and parentage frameworks assume a gestating person